Matt Phipps
Stock Analyst at William Blair
(2.59)
# 2,132
Out of 5,148 analysts
24
Total ratings
47.06%
Success rate
6.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Initiates: Outperform | n/a | $5.68 | - | 1 | Jan 5, 2026 | |
| EVMN Evommune | Initiates: Outperform | n/a | $25.61 | - | 1 | Dec 1, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $7.07 | - | 3 | Oct 17, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | n/a | $7.07 | - | 1 | Oct 16, 2025 | |
| INSM Insmed | Initiates: Outperform | n/a | $146.32 | - | 1 | Aug 20, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Market Perform | n/a | $10.90 | - | 2 | Jul 14, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | n/a | $1.35 | - | 2 | Jul 7, 2025 | |
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $2.29 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $12.28 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $29.65 | - | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.91 | - | 1 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.70 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.62 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.99 | - | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $62.34 | - | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.42 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.22 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $188.05 | - | 2 | Jun 8, 2021 |
Compass Therapeutics
Jan 5, 2026
Initiates: Outperform
Price Target: n/a
Current: $5.68
Upside: -
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: n/a
Current: $25.61
Upside: -
Kezar Life Sciences
Oct 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $7.07
Upside: -
Climb Bio
Oct 16, 2025
Initiates: Outperform
Price Target: n/a
Current: $7.07
Upside: -
Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $146.32
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $10.90
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.35
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $2.29
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $12.28
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $29.65
Upside: -
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $13.91
Upside: -
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.70
Upside: -
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $11.62
Upside: -
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $15.99
Upside: -
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $62.34
Upside: -
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $13.42
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.22
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $188.05
Upside: -